Biophta is a healthcare startup founded in 2020 by two entrepreneurs with a strong background in ophthalmic therapy development. The company aims to radically improve the efficacy of eye treatments through innovative drug delivery systems. Biophta's flagship product is a 7-day continuous microdosing pharmaceutical form that allows patients to self-administer dry mini-tablets, which instantly turn into a gel that adheres firmly to the eye surface. This non-invasive ocular insert provides controlled, low-dose drug release over the span of one week, addressing the current unmet medical needs in ophthalmology and improving patient adherence to treatments. The company is addressing the lack of innovation in ocular drug delivery, a critical issue which has resulted in millions of people losing sight despite having access to effective medication.Number of Partnerships: 10
